NSAIDS and DMARDs Flashcards Preview

Dental Pharmacology > NSAIDS and DMARDs > Flashcards

Flashcards in NSAIDS and DMARDs Deck (48)
Loading flashcards...
1
Q

acetylsalisylic acid

A

aspirin

2
Q

acetaminophen

A

tylenol

3
Q

celecoxib: only COX2 inhibitor

A

celebrex

4
Q

COX2 is inducible by …

A

cytokines

5
Q

NSAIDs do not inhibit …

A

lipoxygenase

6
Q

protection from cardiovascular disease is additional use of which NSAID

A

aspirin

7
Q

which drug will close the ductus in neonates when it has remained patent

A

indomethacin

8
Q

most common side effect of NSAIDs is …

A

gastric or intestinal ulceration

9
Q

all NSAIDs except … tend to cause GI side effects

A

acetaminophen

10
Q

aspirin covalently modifies both COX1 and COX2 … … cyclooxygenase activity

A

irreversibly inhibiting

11
Q

aspirin … COX enzymes

A

acetylates

12
Q

side effects of which NSAID?: GI ulceration, tinnitus, reyes syndrome

A

aspirin

13
Q

hepatic toxicity is a major side effect of which NSAID?

A

acetaminophen

14
Q

therapeutic doses of … do not produce gastric irritation or increase bleeding time

A

acetaminophen

15
Q

antiinflammatory, analgesic, antipyretic; one of the more potent inhibitors of COX; useful for treatment of arthritis, gout; contraindicated in pregnancy

A

indomethacin

16
Q

NSAID for postop pain and inflammation; administered intramuscularly or orally; inflammatory conditions in eye

A

ketorolac

17
Q

potency is greater than indomethacin; non recommended for pregnant women; elevation of hepatic aminotransferase activities in plasma

A

diclofenac

18
Q

approved as a transdermal NSAID

A

diclofenac

19
Q

formulation of diclofenac and misoprotol (PGE1 analog) together that provides gastric protection

A

arthrotec

20
Q

propionic acid derivatives

A

ibuprofen, naproxen, oxaprozin

21
Q

half life of ibuprofen

A

2 hrs

22
Q

half life of naproxen

A

14 hrs

23
Q

half life of oxaprozin

A

40 hrs

24
Q

equivalent of indomethacin or naproxen; principal advantage is its long half life of 50 hrs

A

piroxicam

25
Q

more selective COX2 inhibitor although it will inhibit COX1

A

meloxicam

26
Q

all NSAIDs … hypotensive effect of antihypertensives

A

decrease

27
Q

all NSAIDs … natriuretic and diuretic effects of diuretic agents

A

decrease

28
Q

all NSAIDs … anticoagulant effect of oral anticoagulants

A

increase

29
Q

treatment of all NSAIDs with potassium sparing diuretics, ACE inhibitors, B blockers has potential for

A

hyperkalemia

30
Q

selective COX2 inhibitor; potential for CV problems

A

celecoxib

31
Q

very commonly used DMARD; inhibitor of dihydrofolate reductase and interferes with de novo purine biosynthesis; has been used in treatment of various leukemias; treamtent of psoriasis

A

methotrexate

32
Q

therapeutic effects of methotrexate are within … weeks

A

4-6

33
Q

…. supplements are recommended with methotrexate

A

folic acid

34
Q

methotrexate can by co-administered with …

A

glucocorticoids

35
Q

2nd line DMARD; oral pyrimidine synthesis inhibitor; side effect of hepatic toxicity and liver failure

A

leflunomide

36
Q

antimalarial agent and 2nd live agent used for mild rheumatoid athritis

A

hydroxychloroquine

37
Q

treats RA, ulcertive colitis, Crohn’s; prodrug; colonic bacteria release; 5-aminosalicylic acid–>therapeutic benefit

A

sulfasalazine

38
Q

elevated … levels found in synovial fluid of RA patients

A

TNF

39
Q

major side effect of which class?: increased risk of infections

A

TNF inhibitors

40
Q

decrease TNFa levels; false receptor; may be used in combo with methotrexate, NSAIDs or other agents (except antibodies directed against cytokines)

A

etanercept (enbrel)

41
Q

chimeric IgG1 monoclonal antibody; high affinity binding to TNFa; inhibits interaction of TNFa with its receptors

A

infliximab (remicade)

42
Q

human monoclonal TNFa antibody with human IgG; may be administered with other DMARDs (except biologics) or NSAIDs

A

adalimumab (humira)

43
Q

TNF human monoclonal antibody; administered as monthly SQ injection

A

golimumab

44
Q

TNF antibody conjugated to polyethylene glycol; monthly SQ injection

A

certolizumab

45
Q

interleukin 1 receptor antagonist; one amino acid difference from IL 1; competitively inhibits IL 1

A

anakinra

46
Q

T cell co stimulatory blocker; CTLA4 binds CD80 on antigen presenting cell and prevents interaction with CD20 on T cell

A

abatacept

47
Q

depletes B cells; chimeric monoclonal antibody against CD20 on B cell surface

A

rituximab

48
Q

monoclonal antibody against the IL 6 receptor

A

tocilzumab